{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:16:26Z","timestamp":1790774186724,"version":"4.1.0"},"reference-count":197,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T00:00:00Z","timestamp":1619913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["100933"],"award-info":[{"award-number":["100933"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Even though allogeneic stem cell transplantation is the most intensive treatment for acute myeloid leukemia (AML), chemo-resistant leukemia relapse is still one of the most common causes of death for these patients, as is transplant-related mortality, i.e., graft versus host disease, infections, and organ damage. These relapse patients are not always candidates for additional intensive therapy or re-transplantation, and many of them have decreased quality of life and shortened expected survival. The efficiency of azacitidine for treatment of posttransplant AML relapse has been documented in several clinical trials. Valproic acid is an antiepileptic fatty acid that exerts antileukemic activity through histone deacetylase inhibition. The combination of valproic acid and all-trans retinoic acid (ATRA) is well tolerated even by unfit or elderly AML patients, and low-toxicity chemotherapy (e.g., azacitidine) can be added to this combination. The triple combination of azacitidine, valproic acid, and ATRA may therefore represent a low-intensity and low-toxicity alternative for these patients. In the present review, we review and discuss the general experience with valproic acid\/ATRA in AML therapy and we discuss its possible use in low-intensity\/toxicity treatment of post-allotransplant AML relapse. Our discussion is further illustrated by four case reports where combined treatments with sequential azacitidine\/hydroxyurea, valproic acid, and ATRA were used.<\/jats:p>","DOI":"10.3390\/ph14050423","type":"journal-article","created":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T08:05:21Z","timestamp":1619942721000},"page":"423","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia\u2014Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation"],"prefix":"10.3390","volume":"14","author":[{"given":"\u00d8ystein","family":"Bruserud","sequence":"first","affiliation":[{"name":"Department of Clinical Science, University of Bergen, N-5021 Bergen, Norway"},{"name":"Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Tsykunova","sequence":"additional","affiliation":[{"name":"Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9347-7841","authenticated-orcid":false,"given":"Maria","family":"Hernandez-Valladares","sequence":"additional","affiliation":[{"name":"The Proteomics Facility of the University of Bergen (PROBE), University of Bergen, N-5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5439-8411","authenticated-orcid":false,"given":"Hakon","family":"Reikvam","sequence":"additional","affiliation":[{"name":"Department of Clinical Science, University of Bergen, N-5021 Bergen, Norway"},{"name":"Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor Henrik Anderson","family":"Tvedt","sequence":"additional","affiliation":[{"name":"Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/156800913804486656","article-title":"Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?","volume":"13","author":"Reivam","year":"2013","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Rautenberg, C., Germing, U., Haas, R., Kobbe, G., and Schroeder, T. (2019). Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: Prevention, detection, and treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010228"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1868-7083-5-12","article-title":"Histone deacetylase inhibition in the treatment of acute myeloid leukemia: The effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents","volume":"5","author":"Fredly","year":"2013","journal-title":"Clin. Epigenetics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1080\/15384101.2020.1810402","article-title":"All-trans retinoic acid in non-promyelocytic acute myeloid leukemia: Driver lesion dependent effects on leukemic stem cells","volume":"19","author":"Nguyen","year":"2020","journal-title":"Cell. Cycle"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gronningsaeter, I.S., Fredly, H.K., Gjertsen, B.T., Hatfield, K.J., and Bruserud, \u00d8. (2019). Systemic metabolomic profiling of acute myeloid leukemia patients before and during disease-stabilizing treatment based on all-trans retinoic acid, valproic acid, and low-dose chemotherapy. Cells, 8.","DOI":"10.3390\/cells8101229"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Martino, O.D., and Welch, J.S. (2019). Retinoic acid receptors in acute myeloid leukemia therapy. Cancers, 11.","DOI":"10.3390\/cancers11121915"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00043426-200001000-00012","article-title":"Hematologic toxicity of sodium valproate","volume":"22","author":"Acharya","year":"2000","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/sctm.19-0199","article-title":"Expansion and preservation of the functional activity of adult hematopoietic stem cells cultured ex vivo with a histone deacetylase inhibitor","volume":"9","author":"Zimran","year":"2020","journal-title":"Stem. Cells. Transl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/dvdy.23906","article-title":"Regulation of primitive hematopoiesis by class I histone deacetylases","volume":"242","author":"Shah","year":"2013","journal-title":"Dev. Dyn."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bcp.2010.11.011","article-title":"Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway","volume":"81","author":"Chateauvieux","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/0008-5472.CAN-04-3011","article-title":"Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells","volume":"65","author":"Bug","year":"2005","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1128\/MCB.01360-05","article-title":"Btg2 enhances retinoic acid-induced differentiation by modulating histone H4 methylation and acetylation","volume":"26","author":"Passeri","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-94-017-9050-5_7","article-title":"The roles of retinoic acid and retinoic acid receptors in inducing epigenetic changes","volume":"70","author":"Urvalek","year":"2014","journal-title":"Subcell. Biochem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5875","DOI":"10.1158\/0008-5472.CAN-05-4048","article-title":"Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: Mechanism and utility in enhancing selective growth inhibition by antifolates","volume":"66","author":"Qi","year":"2006","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/sj.leu.2403773","article-title":"The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells","volume":"19","author":"Trus","year":"2005","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/0973-1482.137937","article-title":"Epigenetic therapy of cancer with histone deacetylase inhibitors","volume":"10","author":"Lakshmaiah","year":"2014","journal-title":"J. Cancer Res. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"479364","DOI":"10.1155\/2010\/479364","article-title":"Molecular and therapeutic potential and toxicity of valproic acid","volume":"2010","author":"Chateauvieux","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","article-title":"Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors","volume":"19","author":"Bradbury","year":"2005","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.19.01053","article-title":"DECIDER study team. Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: Results of a multicenter, randomized, 2 \u00d7 2, Phase II Trial","volume":"38","author":"Grishina","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3892\/mmr.2013.1834","article-title":"Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi1 leukemia cells","volume":"9","author":"Zhang","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1124\/jpet.106.118406","article-title":"Targeting AML1\/ETO-histone deacetylase repressor complex: A novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1\/ETO-positive acute myeloid leukemia cells","volume":"321","author":"Liu","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1517\/13543784.17.11.1623","article-title":"In vivo biological effects of ATRA in the treatment of AML","volume":"17","author":"Ryningen","year":"2008","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11001","DOI":"10.1007\/s13277-016-4985-2","article-title":"Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia","volume":"37","author":"Davood","year":"2016","journal-title":"Tumour. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Forthun, R.B., Sengupta, T., Skjeldam, H.K., Lindvall, J.M., McCormack, E., Gjertsen, B.T., and Nilsen, H. (2012). Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048992"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.leukres.2009.05.014","article-title":"Valproic acid exerts differential effects on CXCR4 expression in leukemic cells","volume":"34","author":"Gul","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_26","first-page":"1529","article-title":"Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors","volume":"31","author":"Stapnes","year":"2007","journal-title":"Int. J. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8903","DOI":"10.1158\/0008-5472.CAN-05-2726","article-title":"Sequential valproic acid\/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia","volume":"66","author":"Cimino","year":"2006","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Reikvam, H., Hovland, R., Forthun, R.B., Erdal, S., Gjertsen, B.T., Fredly, H., and Bruserud, \u00d8. (2017). Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia\u2014identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3620-y"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/15592294.2016.1187350","article-title":"Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks","volume":"11","author":"Lang","year":"2016","journal-title":"Epigenetics"},{"key":"ref_30","first-page":"733","article-title":"Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors","volume":"6","author":"Zhang","year":"2013","journal-title":"Onco. Targets Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00432-019-02931-1","article-title":"Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia","volume":"145","author":"Forthun","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Hernandez-Valladares, M., Wangen, R., Aaseb\u00f8, E., Reikvam, H., Berven, F.S., Selheim, F., and Bruserud, \u00d8. (2021). Proteomic studies of primary acute myeloid leukemia cells derived from patients before and during disease-stabilizing treatment based on all-trans retinoic acid and valproic acid. Cancers, 13.","DOI":"10.3390\/cancers13092143"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/jcb.20544","article-title":"Induction of osteogenic differentiation of human mesenchymal stem cells by histone deacetylase inhibitors","volume":"96","author":"Cho","year":"2005","journal-title":"J. Cell. Biochem."},{"key":"ref_34","first-page":"143479","article-title":"In Vitro characterization of valproic acid, atra, and cytarabine used for disease-stabilization in human acute myeloid leukemia: Antiproliferative effects of drugs on endothelial and osteoblastic cells and altered release of angioregulatory mediators by endothelial cells","volume":"2014","author":"Kvestad","year":"2014","journal-title":"Leuk. Res. Treat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.leukres.2008.10.005","article-title":"A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid","volume":"33","author":"Ryningen","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ersvaer, E., Brenner, A.K., Vetas, K., Reikvam, H., and Bruserud, \u00d8. (2015). Effects of cytarabine on activation of human T cells\u2014Cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid. BMC Pharmacol. Toxicol., 16.","DOI":"10.1186\/s40360-015-0012-2"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1868-7083-5-13","article-title":"The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia","volume":"5","author":"Fredly","year":"2013","journal-title":"Clin. Epigenetics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.imbio.2014.03.013","article-title":"Histone deacetylase inhibitor valproic acid affects plasmacytoid dendritic cells phenotype and function","volume":"219","author":"Arbez","year":"2014","journal-title":"Immunobiology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/jcp.25604","article-title":"Valproic acid and lithium meditate anti-inflammatory effects by differentially modulating dendritic cell differentiation and function","volume":"232","author":"Leu","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.imbio.2011.11.010","article-title":"Impact of valproic acid on dendritic cells function","volume":"217","author":"Frikeche","year":"2012","journal-title":"Immunobiology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1158\/1078-0432.CCR-06-2903","article-title":"Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity","volume":"13","author":"Nencioni","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Delgado, F.G., Cardenas, P., and Castellanos, J.E. (2018). Valproic acid downregulates cytokine expression in human macrophages infected with dengue virus. Diseases, 6.","DOI":"10.3390\/diseases6030059"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10067-017-3922-0","article-title":"Sodium valproate modulates immune response by alternative activation of monocyte-derived macrophages in systemic lupus erythematosus","volume":"37","author":"Mohammadi","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13287-017-0553-y","article-title":"Immunosuppressive capacity of mesenchymal stem cells correlates with metabolic activity and can be enhanced by valproic acid","volume":"8","author":"Killer","year":"2017","journal-title":"Stem. Cell. Res. Ther."},{"key":"ref_45","first-page":"14","article-title":"Chemically primed bone-marrow derived mesenchymal stem cells show enhanced expression of chemokine receptors contributed to their migration capability","volume":"19","author":"Bidkhori","year":"2016","journal-title":"Iran. J. Basic Med. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ajh.23116","article-title":"Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment","volume":"87","author":"Fredly","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cyto.2016.05.014","article-title":"Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis","volume":"84","author":"Pulliam","year":"2016","journal-title":"Cytokine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/138945006776359467","article-title":"Histone deacetylases as targets for dietary cancer preventive agents: Lessons learned with butyrate, diallyl disulfide, and sulforaphane","volume":"7","author":"Myzak","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2174\/138945012804545443","article-title":"Anticarcinogenic actions of tributyrin, a butyric acid prodrug","volume":"13","author":"Heidor","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Brenner, A.K., and Bruserud, \u00d8. (2019). Functional Toll-Like Receptors (TLRs) are expressed by a majority of primary human acute myeloid leukemia cells and inducibility of the tlr signaling pathway is associated with a more favorable phenotype. Cancers, 11.","DOI":"10.3390\/cancers11070973"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1210\/en.2009-1140","article-title":"Toll-like receptor ligands cause proinflammatory and prodiabetic activation of adipocytes via phosphorylation of extracellular signal-regulated kinase and c-Jun N-terminal kinase but not interferon regulatory factor-3","volume":"151","author":"Kopp","year":"2010","journal-title":"Endocrinology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1007\/s00125-017-4401-5","article-title":"VLDL and apolipoprotein CIII induce ER stress and inflammation and attenuate insulin signalling via Toll-like receptor 2 in mouse skeletal muscle cells","volume":"60","author":"Botteri","year":"2017","journal-title":"Diabetologia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5551\/jat.E607","article-title":"Apolipoprotein CIII links dyslipidemia with atherosclerosis","volume":"16","author":"Kawakami","year":"2009","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.exphem.2017.04.007","article-title":"Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation","volume":"52","author":"Verhagen","year":"2017","journal-title":"Exp. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Rossetti, S., and Sacchi, N. (2020). Emerging cancer epigenetic mechanisms regulated by all-trans retinoic acid. Cancers, 12.","DOI":"10.3390\/cancers12082275"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Giuli, M.V., Hanieh, P.N., Giuliani, E., Rinaldi, F., Marianecci, C., Screpanti, I., Checquolo, S., and Carafa, M. (2020). Current trends in ATRA delivery for cancer therapy. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12080707"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"109802","DOI":"10.1016\/j.biopha.2019.109802","article-title":"Long non-coding RNA SNHG5 regulates chemotherapy resistance through the miR-32\/DNAJB9 axis in acute myeloid leukemia","volume":"123","author":"Wang","year":"2020","journal-title":"Biomed. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Nguyen, C.H., Grandits, A.M., Vassiliou, G.S., Staber, P.B., Heller, G., and Wieser, R. (2020). Evi1 Counteracts anti-leukemic and stem cell inhibitory effects of all-trans retinoic acid on Flt3-ITD\/Npm1Driven acute myeloid leukemia cells. Biomedicines, 8.","DOI":"10.3390\/biomedicines8100385"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/sj.leu.2403528","article-title":"Study Group Ulm. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia","volume":"18","author":"Schlenk","year":"2004","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3324\/haematol.13378","article-title":"Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B","volume":"94","author":"Schlenk","year":"2009","journal-title":"Haematologica"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood-2007-03-080523","article-title":"MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML","volume":"110","author":"Heuser","year":"2007","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2009-08-236588","article-title":"The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: Overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA","volume":"115","author":"Burnett","year":"2010","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00277-016-2810-z","article-title":"All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: Results of the randomized AMLSG 07-04 study","volume":"95","author":"Schlenk","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_64","first-page":"CD011960","article-title":"Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL))","volume":"8","author":"Kreuzer","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.3324\/haematol.2018.192807","article-title":"Antitumor synergy with SY-1425, a selective RAR\u03b1 agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia","volume":"104","author":"McKeown","year":"2019","journal-title":"Haematologica"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1182\/blood-2006-09-045781","article-title":"Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia","volume":"109","author":"Fazi","year":"2007","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Su, M., Alonso, S., Jones, J.W., Yu, J., Kane, M.A., Jones, R.J., and Ghiaur, G. (2015). All-trans retinoic acid activity in acute myeloid leukemia: Role of cytochrome P450 enzyme expression by the microenvironment. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127790"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2014-11-611459","article-title":"Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells","volume":"125","author":"Martelli","year":"2015","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2014-11-612416","article-title":"Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells","volume":"125","author":"Dassouki","year":"2015","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1084\/jem.20150736","article-title":"Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia","volume":"213","author":"Boutzen","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/gcc.20532","article-title":"Expression and prognostic significance of different mRNA 5\u2032-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1\/EVI1 overexpression both predict short remission duration","volume":"47","author":"Haas","year":"2008","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1182\/blood-2007-10-119230","article-title":"High EVI1 levels predict adverse outcome in acute myeloid leukemia: Prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated","volume":"111","author":"Lugthart","year":"2008","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2009.26.0646","article-title":"High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities","volume":"28","author":"Lugthart","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/sj.leu.2400547","article-title":"Expression of the Zn finger gene, EVI-1, in acute promyelocytic leukemia","volume":"11","author":"Xi","year":"1997","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.gene.2005.04.032","article-title":"Regulation of the expression of the oncogene EVI1 through the use of alternative mRNA 5\u2032-ends","volume":"356","author":"Aytekin","year":"2005","journal-title":"Gene"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1111\/j.1742-4658.2009.07398.x","article-title":"Zinc finger transcription factor ecotropic viral integration site 1 is induced by all-trans retinoic acid (ATRA) and acts as a dual modulator of the ATRA response","volume":"276","author":"Bingemann","year":"2009","journal-title":"FEBS J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.4161\/15384101.2014.946869","article-title":"The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid","volume":"13","author":"Steinmetz","year":"2014","journal-title":"Cell. Cycle"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood-2015-07-653840","article-title":"Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid","volume":"127","author":"Verhagen","year":"2016","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/s41419-019-2172-2","article-title":"All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia","volume":"10","author":"Nguyen","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00280-016-3213-5","article-title":"Use of retinoic acid\/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells","volume":"79","author":"Moreb","year":"2017","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cbi.2017.06.020","article-title":"ALDHs in normal and malignant hematopoietic cells: Potential new avenues for treatment of AML and other blood cancers","volume":"276","author":"Gasparetto","year":"2017","journal-title":"Chem. Biol. Interact."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"24734","DOI":"10.18632\/aging.202361","article-title":"Biological characteristics of aging in human acute myeloid leukemia cells: The possible importance of aldehyde dehydrogenase, the cytoskeleton and altered transcriptional regulation","volume":"12","author":"Berven","year":"2020","journal-title":"Aging"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.stem.2017.06.002","article-title":"Retinoic acid puts hematopoietic stem cells back to sleep","volume":"21","author":"Pronk","year":"2017","journal-title":"Cell. Stem. Cell."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Ca\u00f1ete, A., Cano, E., Mu\u00f1oz-Ch\u00e1puli, R., and Carmona, R. (2017). Role of vitamin A\/retinoic acid in regulation of embryonic and adult hematopoiesis. Nutrients, 9.","DOI":"10.3390\/nu9020159"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Bono, M.R., Tejon, G., Flores-Santiba\u00f1ez, F., Fernandez, D., Rosemblatt, M., and Sauma, D. (2016). Retinoic acid as a modulator of t cell immunity. Nutrients, 8.","DOI":"10.3390\/nu8060349"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6525787","DOI":"10.1155\/2020\/6525787","article-title":"All-trans retinoic acid inhibits bone marrow mesenchymal stem cell commitment to adipocytes via upregulating FRA1 signaling","volume":"2020","author":"Xie","year":"2020","journal-title":"Int. J. Endocrinol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/2211-5463.12792","article-title":"All-trans retinoic acid and human salivary histatin-1 promote the spreading and osteogenic activities of pre-osteoblasts in vitro","volume":"10","author":"Sun","year":"2020","journal-title":"FEBS Open Bio"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.2147\/DDDT.S178190","article-title":"All-trans retinoic acid can antagonize osteoblastogenesis induced by different BMPs irrespective of their dimerization types and dose-efficiencies","volume":"12","author":"Liu","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e23287","DOI":"10.1002\/dvg.23287","article-title":"Retinoic acid signaling in vascular development","volume":"57","author":"Pawlikowski","year":"2019","journal-title":"Genesis"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Li, N., Lu, Y., Li, D., Zheng, X., Lian, J., Li, S., Cui, H., Zhang, L., Sang, L., and Wang, Y. (2017). All-trans retinoic acid suppresses the angiopoietin-Tie2 pathway and inhibits angiogenesis and metastasis in esophageal squamous cell carcinoma. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174555"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.it.2016.12.006","article-title":"Retinoic acid and immune homeostasis: A balancing act","volume":"38","author":"Erkelens","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Huang, Z., Liu, Y., Qi, G., Brand, D., and Zheng, S.G. (2018). Role of vitamin A in the immune system. J. Clin. Med., 7.","DOI":"10.3390\/jcm7090258"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3067126","DOI":"10.1155\/2018\/3067126","article-title":"Impact of retinoic acid on immune cells and inflammatory diseases","volume":"2018","author":"Oliveira","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.4049\/jimmunol.1303245","article-title":"Modulation of T cell and innate immune responses by retinoic Acid","volume":"192","author":"Raverdeau","year":"2014","journal-title":"J. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1166S","DOI":"10.3945\/ajcn.112.034637","article-title":"Vitamin A and retinoic acid in T cell-related immunity","volume":"96","author":"Ross","year":"2012","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"8658156","DOI":"10.1155\/2018\/8658156","article-title":"All-trans retinoic acid induces CD4+CD25+FOXP3+ regulatory T cells by increasing FOXP3 demethylation in systemic sclerosis CD4+ T cells","volume":"2018","author":"Sun","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/imm.12768","article-title":"Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8+ T-cell immunity","volume":"152","author":"Yin","year":"2017","journal-title":"Immunology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","article-title":"Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas","volume":"4","author":"Long","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3389\/fimmu.2017.01560","article-title":"All-Trans retinoic acid promotes an M1- to M2-phenotype shift and inhibits macrophage-mediated immunity to leishmania major","volume":"8","author":"Vellozo","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1586\/ehm.11.54","article-title":"The chemokine system in allogeneic stem-cell transplantation: A possible therapeutic target?","volume":"4","author":"Melve","year":"2011","journal-title":"Expert Rev. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Rundgren, I.M., Ersv\u00e6r, E., Ahmed, A.B., Ryningen, A., and Bruserud, \u00d8. (2020). A Pilot Study of Circulating Monocyte Subsets in Patients Treated with Stem Cell Transplantation for High-Risk Hematological Malignancies. Medicina, 56.","DOI":"10.3390\/medicina56010036"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Rundgren, I.M., Ersv\u00e6r, E., Ahmed, A.B., Ryningen, A., and Bruserud, \u00d8. (2019). Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation\u2014A study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients. BMC Immunol., 20.","DOI":"10.1186\/s12865-019-0323-y"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.bbmt.2019.10.005","article-title":"The systemic metabolic profile early after allogeneic stem cell transplantation: Effects of adequate energy support administered through enteral feeding tube","volume":"26","author":"Tvedt","year":"2020","journal-title":"Biol. Blood Marrow. Transplant."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Martinez-Cibrian, N., Zeiser, R., and Perez-Simon, J.A. (2020). Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions. Blood Rev., 100792. Epub ahead of print.","DOI":"10.1016\/j.blre.2020.100792"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.immuni.2015.06.009","article-title":"Retinoic acid differentially regulates the migration of innate lymphoid cell subsets to the gut","volume":"43","author":"Kim","year":"2015","journal-title":"Immunity"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Czarnewski, P., Das, S., Parigi, S.M., and Villablanca, E.J. (2017). Retinoic acid and its role in modulating intestinal innate immunity. Nutrients, 9.","DOI":"10.3390\/nu9010068"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Koenecke, C., Prinz, I., Bubke, A., Schreder, A., Lee, C.W., Pabst, O., and F\u00f6rster, R. (2012). Shift of graft-versus-host-disease target organ tropism by dietary vitamin A. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038252"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.bbmt.2016.09.001","article-title":"Effects of donor vitamin a deficiency and pharmacologic modulation of donor t cell retinoic acid pathway on the severity of experimental graft-versus-host disease","volume":"22","author":"Dodge","year":"2016","journal-title":"Biol. Blood Marrow. Transpl."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1182\/blood-2012-08-445130","article-title":"A critical role for the retinoic acid signaling pathway in the pathophysiology of gastrointestinal graft-versus-host disease","volume":"121","author":"Chen","year":"2013","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.4049\/jimmunol.1800899","article-title":"Dendritic cell expression of retinal aldehyde dehydrogenase-2 controls graft-versus-host disease lethality","volume":"202","author":"Thangavelu","year":"2019","journal-title":"J. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood-2017-02-765826","article-title":"Lower levels of vitamin A are associated with increased gastrointestinal graft-versus-host disease in children","volume":"129","author":"Lounder","year":"2017","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fmed.2017.00067","article-title":"Serum vitamin a levels may affect the severity of ocular graft-versus-host disease","volume":"4","author":"Tong","year":"2017","journal-title":"Front. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13148-011-0031-9","article-title":"Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid","volume":"2","author":"Kuendgen","year":"2011","journal-title":"Clin. Epigenetics"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cncr.21552","article-title":"The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia","volume":"106","author":"Kuendgen","year":"2006","journal-title":"Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00277-005-0026-8","article-title":"Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia","volume":"84","author":"Kuendgen","year":"2005","journal-title":"Ann. Hematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3324\/haematol.10758","article-title":"Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia","volume":"92","author":"Bug","year":"2007","journal-title":"Haematologica"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/cncr.21589","article-title":"Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia","volume":"104","author":"Bug","year":"2005","journal-title":"Cancer"},{"key":"ref_118","first-page":"986","article-title":"Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia","volume":"90","author":"Raffoux","year":"2005","journal-title":"Haematologica"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3109\/10428194.2011.642302","article-title":"Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity","volume":"53","author":"Lane","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.leukres.2011.02.021","article-title":"Hematologic improvement and response in elderly AML\/RAEB patients treated with valproic acid and low-dose Ara-C","volume":"35","author":"Corsetti","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Xie, C., Drenberg, C., Edwards, H., Caldwell, J.T., Chen, W., Inaba, H., Xu, X., Buck, S.A., Taub, J.W., and Baker, S.D. (2013). Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0079106"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41375-018-0293-8","article-title":"Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: Predominant synergistic gene downregulation associated with gene body demethylation","volume":"33","author":"Schlosser","year":"2019","journal-title":"Leukemia"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3324\/haematol.2015.129577","article-title":"Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib\/II panobidara study","volume":"100","author":"Ocio","year":"2015","journal-title":"Haematologica."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/leu.2017.242","article-title":"Phase I\/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)","volume":"31","author":"Bug","year":"2017","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/leu.2013.38","article-title":"Phase Ia\/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies","volume":"27","author":"DeAngelo","year":"2013","journal-title":"Leukemia"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1158\/1078-0432.CCR-06-0511","article-title":"A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies","volume":"12","author":"Giles","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/1078-0432.CCR-13-1576","article-title":"Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients","volume":"20","author":"Govindaraj","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/nm1652","article-title":"Deacetylase inhibition promotes the generation and function of regulatory T cells","volume":"13","author":"Tao","year":"2007","journal-title":"Nat. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/annrheumdis-2011-200593","article-title":"HDAC inhibitor therapy in autoimmunity and transplantation","volume":"71","author":"Hancock","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-19-0171","article-title":"Histone deacetylase inhibition with panobinostat combined with intensive induction chemotherapy in older patients with acute myeloid leukemia: Phase I study results","volume":"25","author":"Wieduwilt","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1182\/bloodadvances.2020002074","article-title":"Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation","volume":"4","author":"Kalin","year":"2020","journal-title":"Blood Adv."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/leu.2017.159","article-title":"A phase 1b\/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with \u2a7d30% blasts","volume":"31","author":"Sekeres","year":"2017","journal-title":"Leukemia"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3324\/haematol.2015.140996","article-title":"Clinical activity of azacitidine in patients who relapse after allogeneic stem cell ransplantation for acute myeloid leukemia","volume":"101","author":"Craddock","year":"2016","journal-title":"Haematologica"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"388","DOI":"10.2174\/138920107783018417","article-title":"Histone deacetylase inhibitors in cancer treatment: A review of the clinical toxicity and the modulation of gene expression in cancer cell","volume":"8","author":"Bruserud","year":"2007","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/bmt.2009.222","article-title":"Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting","volume":"45","author":"Lubbert","year":"2010","journal-title":"Bone Marrow. Transplant."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1179\/102453310X12647083620967","article-title":"Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia\u2014a report of five cases","volume":"15","author":"Fredly","year":"2010","journal-title":"Hematology"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Grishina, O., Schmoor, C., D\u00f6hner, K., Hackanson, B., Lubrich, B., May, A.M., Cieslik, C., M\u00fcller, M.J., and L\u00fcbbert, M. (2015). DECIDER: Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1432-5"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","article-title":"Phase 1\/2 study of the combination of 5-aza-2\u2032-deoxycytidine with valproic acid in patients with leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","article-title":"Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia","volume":"25","author":"Blum","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cncr.22891","article-title":"Valproic acid for the treatment of myeloid malignancies","volume":"110","author":"Kuendgen","year":"2007","journal-title":"Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-020-01017-7","article-title":"Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Xuan","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s12185-017-2364-4","article-title":"Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation","volume":"107","author":"Schroeder","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/bmt.2009.266","article-title":"5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: A retrospective analysis","volume":"45","author":"Czibere","year":"2010","journal-title":"Bone Marrow. Transpl."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/bmt.2015.10","article-title":"5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft","volume":"50","author":"Steinmann","year":"2015","journal-title":"Bone Marrow. Transpl."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/bmt.2013.233","article-title":"Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT","volume":"49","author":"Tessoulin","year":"2014","journal-title":"Bone Marrow Transpl."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.bbmt.2014.12.016","article-title":"Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions\u2014A retrospective multicenter analysis from the German Cooperative Transplant Study Group","volume":"21","author":"Schroeder","year":"2015","journal-title":"Biol. Blood Marrow. Transpl."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbmt.2016.10.016","article-title":"Factors determining responses to azacitidine in patients with myelodysplastic syndromes and acute myeloid leukemia with early post-transplantation relapse: A prospective trial","volume":"23","author":"Woo","year":"2017","journal-title":"Biol. Blood Marrow. Transpl."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.leukres.2018.07.005","article-title":"Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation","volume":"72","author":"Sommer","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00277-017-3185-5","article-title":"Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"97","author":"Schroeder","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JCO.18.00889","article-title":"Combination lenalidomide and azacitidine: A novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia","volume":"37","author":"Craddock","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Thakar, M.S., and Forman, S.J. (2009). ASH evidence-based guidelines: Is there a role for second allogeneic transplant after relapse?. Hematol. Am. Soc. Hematol. Educ. Program, 414\u2013418.","DOI":"10.1182\/asheducation-2009.1.414"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1002\/cncr.29430","article-title":"Health care utilization and end-of-life care for older patients with acute myeloid leukemia","volume":"121","author":"Abel","year":"2015","journal-title":"Cancer"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1182\/blood.V126.23.4496.4496","article-title":"Symptom burden, quality of life, and distress in acute myeloid leukemia patients receiving induction chemotherapy: Results of a prospective electronic patient-reported outcomes study","volume":"126","author":"LeBlanc","year":"2015","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1002\/cncr.32397","article-title":"Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission","volume":"125","author":"Slavin","year":"2019","journal-title":"Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00520-014-2333-x","article-title":"End-of-life characteristics and palliative care provision for elderly patients suffering from acute myeloid leukemia","volume":"23","author":"Cheng","year":"2015","journal-title":"Support Care Cancer"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","article-title":"Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: Final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group","volume":"29","author":"Suciu","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","article-title":"Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A cancer and leukemia group B study","volume":"20","author":"Kornblith","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ctrv.2018.07.005","article-title":"Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia","volume":"69","author":"Bosshard","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40487-016-0039-6","article-title":"Health-related quality of life of patients with acute myeloid leukemia: A systematic literature","volume":"5","author":"Korol","year":"2017","journal-title":"Rev. Oncol. Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/sj.leu.2400977","article-title":"Quality of life in adult patients with acute myeloid leukemia receiving intensive and prolonged chemotherapy\u2014A longitudinal study","volume":"12","author":"Schumacher","year":"1998","journal-title":"Leukemia"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ejh.12324","article-title":"Impaired health-related quality of life in acute myeloid leukemia survivors: A single-center study","volume":"93","author":"Leunis","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.11987","article-title":"Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia","volume":"93","author":"Messerer","year":"2008","journal-title":"Haematologica"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bbmt.2011.05.022","article-title":"A prospective study comparing the outcomes and health-related quality of life in adult patients with myeloid malignancies undergoing allogeneic transplantation using myeloablative or reduced-intensity conditioning","volume":"18","author":"Gupta","year":"2012","journal-title":"Biol. Blood Marrow. Transpl."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0959-8049(03)00628-2","article-title":"Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients: Analysis of the UK Medical Research Council AML 10 Trial","volume":"40","author":"Watson","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bmt.2015.137","article-title":"Patient-reported quality of life after allogeneic hematopoietic cell transplantation or chemotherapy for acute leukemia","volume":"50","author":"Kurosawa","year":"2015","journal-title":"Bone Marrow Transpl."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Bazarbachi, A.H., Al Hamed, R., Malard, F., Mohty, M., and Bazarbachi, A. (2019). Allogeneic transplant for FLT3-ITD mutated AML: A focus on FLT3 inhibitors before, during, and after transplant. Ther. Adv. Hematol., 10.","DOI":"10.1177\/2040620719882666"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.3324\/haematol.2012.067629","article-title":"Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): Results of the LENAMAINT trial","volume":"97","author":"Sockel","year":"2012","journal-title":"Haematologica"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/bmt.2017.31","article-title":"Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT","volume":"52","author":"Massoud","year":"2017","journal-title":"Bone Marrow Transpl."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: A dose and schedule finding study","volume":"116","author":"Giralt","year":"2010","journal-title":"Cancer"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.bbmt.2018.06.016","article-title":"CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes","volume":"24","author":"Oran","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/bjh.13248","article-title":"Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia","volume":"169","author":"Oshikawa","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15691","article-title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia\u2014A matched pair analysis by the Acute Leukaemia Working Party of EBMT","volume":"184","author":"Schmid","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): An open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: Results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3892\/ijmm.2016.2552","article-title":"Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis","volume":"37","author":"Liu","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1158\/1078-0432.CCR-10-1707","article-title":"Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia","volume":"16","author":"Xie","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"8105","DOI":"10.18632\/oncotarget.6991","article-title":"Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia","volume":"7","author":"Leitch","year":"2016","journal-title":"Oncotarget"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Heo, S.K., Noh, E.K., Yoon, D.J., Jo, J.C., Park, J.H., and Kim, H. (2014). Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098859"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/leu.2011.315","article-title":"Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia","volume":"26","author":"McCormack","year":"2012","journal-title":"Leukemia"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.3109\/10428194.2012.698273","article-title":"Synergistic\/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells","volume":"53","author":"Nie","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00277-011-1175-6","article-title":"Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells","volume":"90","author":"Wang","year":"2011","journal-title":"Ann. Hematol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/pbc.24152","article-title":"Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells","volume":"59","author":"Xie","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1517\/13543784.2016.1146251","article-title":"Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"25","author":"Stahl","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1080\/13543784.2016.1216971","article-title":"Panobinostat for the treatment of acute myelogenous leukemia","volume":"25","author":"Morabito","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Ungerstedt, J.S. (2018). Epigenetic modifiers in myeloid malignancies: The role of histone deacetylase inhibitors. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19103091"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/13543776.2017.1276565","article-title":"Selective histone deacetylase small molecule inhibitors: Recent progress and perspectives","volume":"27","author":"Qin","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14740338.2019.1615051","article-title":"A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma","volume":"18","author":"Beksac","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.2147\/CMAR.S149241","article-title":"Hematologic toxicity is rare in relapsed patients treated with belinostat: A systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas","volume":"10","author":"Allen","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"5244","DOI":"10.2174\/0929867326666190325095853","article-title":"Immunosuppression and immunotargeted therapy in acute myeloid leukemia\u2014The potential use of checkpoint inhibitors in combination with other treatments","volume":"26","author":"Leufven","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/ajh.25750","article-title":"Harnessing the immune system after allogeneic stem cell transplant in acute myeloid leukemia","volume":"95","author":"Sterling","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Merryman, R.W., Castagna, L., Giordano, L., Ho, V.T., Corradini, P., Guidetti, A., Casadei, B., Bond, D.A., Jaglowski, S., and Spinner, M.A. (2021). Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia, Epub ahead of print.","DOI":"10.1038\/s41375-021-01193-6"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clml.2020.11.018","article-title":"A Phase II trial of imatinib mesylate as maintenance therapy for patients with newly diagnosed c-kit-positive acute myeloid leukemia","volume":"21","author":"Advani","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_196","first-page":"8830123","article-title":"Prolonged response of a patient with relapsed acute myeloid leukemia to a novel oral bromodomain extraterminal inhibitor (BETi)","volume":"2020","author":"Murphy","year":"2020","journal-title":"Case Rep. Hematol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: A single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet. Haematol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/5\/423\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:56:40Z","timestamp":1760162200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/5\/423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,2]]},"references-count":197,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["ph14050423"],"URL":"https:\/\/doi.org\/10.3390\/ph14050423","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,2]]}}}